

1. [Medical device maker Medtronic to buy HeartWare for \\$1.1 billion](#) – Reuters

Medtronic Plc (MDT.N) said it would buy HeartWare International Inc (HTWR.O) for about \$1.1 billion, bulking up its portfolio of devices for treating heart diseases and pushing deeper into the market for less-invasive surgical products. HeartWare shares rose as much as 92 pct to \$57.58 in morning trading on Monday, just below the offer price of \$58 per share in cash. Medtronic shares fell about 2 percent. HeartWare's flagship product, the HVAD System, is placed in the body through a less-invasive surgery and assists with blood flow when the heart is unable to pump blood efficiently.

2. [Even with good healthcare, social factors affect death risk](#) – Reuters

Even in Sweden, a country with universal healthcare, disadvantaged people with diabetes are still more likely to die compared to diabetics with social and economic advantages, a new study finds. The risk of death was affected by marital status, education, immigration history and wealth, even though these factors don't stand in the way of receiving healthcare for the people in the study.

3. [Shri J P Nadda launches new Nurse Practitioner courses and Live Register for Nurses Government committed to providing accessible and affordable quality training for skill upgradation of nurses: Shri J P Nadda](#) – Business Standard

Underscoring the importance of upgradation of skills of nurses across the country, Shri J P Nadda, Union Minister for Health and Family Welfare stated that the Government is committed

1. [Medical device maker Medtronic to buy HeartWare for \\$1.1 billion](#) – Reuters
2. [Even with good healthcare, social factors affect death risk](#) – Reuters
3. [Shri J P Nadda launches new Nurse Practitioner courses and Live Register for Nurses Government committed to providing accessible and affordable quality training for skill upgradation of nurses: Shri J P Nadda](#) – Business Standard
4. ['Brexit offers M&A opportunities'](#) – The Hindu Business Line
5. [Sanofi-BI deal: In search of a pill for growth](#) – The Hindu Business Line
6. [Hetero launches colorectal cancer drug](#) – Business Today
7. [Govt puts cap on prices of 42 essential drugs](#) – The Times of India
8. [TS seeks Centre's nod for Pharma City, NIMZ](#) – The Hindu
9. [NCB to sensitize pharmaceutical industry on illegal use of chemicals](#) – The Indian Express
10. [Bom HC imposes stay order on govt's move to cap drug prices](#) – Moneycontrol.com
11. [PFCD lauds govt initiatives to address growing NCD burden](#) – Express Healthcare
12. [Researchers Find Second 'Superbug' Gene In US Patient](#) – NDTV.com
13. [Spurious drugs kills one million people every year: WHO](#) – The Hans India
14. [Indian pharma segment may not be impacted by Brexit](#) – Pharmabiz.com

to providing accessible, affordable and quality training to them. He also emphasised that the Nursing Staff occupies important position in healthcare delivery and without them the desired results cannot be achieved. The Health Minister informed that the Government has undertaken several initiatives for strengthening of nursing cadre are. Some of these are establishment of ANM/GNM schools, up-gradation of institutions from School of Nursing to College of Nursing, Training of Nurses, development of 11 one year specialization courses, revision of curriculum for all nursing programs, establishment of national PhD consortium for Nursing Research.

4. **[‘Brexit offers M&A opportunities’ – The Hindu Business Line](#)**

Brexit is likely to pose new challenges for global conglomerates. It may also offer new opportunities to India Inc, which is increasing its footprint in the UK and the EU. Speaking to Bloomberg TV India, Biocon CMD Kiran Mazumdar-Shaw said the fall of the pound sterling will benefit Indian companies operating out of the UK.

5. **[Sanofi-BI deal: In search of a pill for growth](#)** – The Hindu Business Line

It may not come as a complete surprise that two more drug majors, Sanofi and Boehringer Ingelheim have entered into a global asset swap agreement, this one a \$ 25 billion transaction. Earlier on Monday, a joint announcement said that French company Sanofi would swap its animal health business (Merial) with Germany-based Boehringer Ingelheim’s (BI) consumer healthcare business (except in China). In a sense, the latest Sanofi-BI deal is on similar lines, reinforcing the message that companies are exploring various avenues in search of that all elusive growth pill, aiming to be in the top deck in the segments they are in.

6. **[Hetero launches colorectal cancer drug](#)** – Business Today

Hyderabad-based pharma major Hetero Drugs has launched its biosimilar 'Bevacizumab' in the Indian market under the brand name 'CizumabTM'. The product is used for the treatment of Metastatic Colorectal Cancer (mCRC). Swiss healthcare giant Roche has filed a lawsuit in the Delhi High Court to prevent the launch of Bevacizumab in India but Hetero Drugs said that there no order against the company.

7. **[Govt puts cap on prices of 42 essential drugs](#)** – The Times of India

The government has decided to put a cap on prices of 42 essential medicines used in treatment of various critical and life-threatening diseases such as tuberculosis, cancer and cardiac diseases. As per reports, the ceiling prescribed by National Pharmaceutical Pricing Authority (NPPA) would bring the cost of these essential drugs down by almost 15 %. The NPPA, in its notification, said it has fixed or revised ceiling prices of 45 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016. Out of the 45, the price of 42 drugs would come down by 15 %.

8. **[TS seeks Centre’s nod for Pharma City, NIMZ](#)** – The Hindu

Telangana IT Minister K.T. Rama Rao on Monday requested Union Minister of State for Commerce Nirmala Seetharaman to help the State get Union Cabinet approval for the two proposed special economic zones - Pharma City and National Investment & Manufacturing Zone (NIMZ). During a meeting with the Union Minister in Delhi, Mr. Rama Rao sought a financial assistance of Rs. 1,500 crore for the development of Pharma City. He claimed that Ms. Seetharaman had agreed to sanction Rs. 200 crore to begin with. He sought financial tax exemption for the SEZs and also sanction of a leather park to the State. Mr. Rama Rao also requested the Union Minister to sanction multi-brand SEZs to Telangana since the existing and proposed ones were single-product based.

9. [**NCB to sensitize pharmaceutical industry on illegal use of chemicals**](#) – **The Indian Express**
Aiming to stop the illegal diversion of certain chemical formulations used to prepare drugs, such as heroin and 'methamphetamine', the Narcotics Control Bureau (NCB) has planned to sensitize the pharmaceutical industry to curb the practice. Apart from concern about abuse of chemicals by drug mafia to manufacture psychotropic drugs, also known as party drugs, NCB officials are also worried about the sale of 'over the counter' medicines, which are used as drugs by many.
10. [**Bom HC imposes stay order on govt's move to cap drug prices**](#) – **Moneycontrol.com**
The Bombay High Court has imposed an interim stay on the government's decision to cap prices of 530 drugs. Pharma companies have already undertaken price cuts on the account of wholesale price index, which was -2.7 percent in 2015, as prescribed by norms of drug price regulator National Pharma Pricing Authority (NPPA). The drug price control order would have impacted sales of Indian pharma companies to the tune of 2 percent of sales.
11. [**PFCD lauds govt initiatives to address growing NCD burden**](#) – **Express Healthcare**
Partnership to Fight Chronic Disease (PFCD) has called upon the government to initiate a comprehensive approach to reduce the burgeoning out-of-pocket expenditure associated with treatment of NCDs. It may be noted that the Union Ministry of Health & Family Welfare has recently launched several key initiatives to address the growing burden of NCDs in India. Dr Kenneth E Thorpe, Chairman, PFCD, "The steps announced by Union Health & Family Welfare minister JP Nadda are commendable, and a clear indication of the government's long-term commitment to find sustainable solutions to address the growing burden of NCDs. What's required for the government now is to realise the importance of increasing investments on healthcare."
12. [**Researchers Find Second 'Superbug' Gene In US Patient**](#) – **NDTV.com**
Scientists have identified a second patient in the United States infected with bacteria carrying the mcr-1 "superbug" gene, which makes bacteria highly resistant to a last-resort class of antibiotics.
The gene, found in a sample of Escherichia coli bacteria from a patient in New York, follows the discovery late last month of a patient in Pennsylvania who had a urinary tract infection caused by E coli that carried the gene.
13. [**Spurious drugs kills one million people every year: WHO**](#) – **The Hans India**
Counterfeiters are lurking in the dark and there's no guarantee that the medicines sold from the drug stores across India are all genuine. A consumer cannot tell whether the pharma product wrapped in sleek packaging isn't fake. India is yet to adopt international solutions which are necessary to authenticate medicines and pharmaceutical products that millions of people depend on to combat health conditions. Unlike Pakistan, India doesn't have a system with which the consumer can check whether a medicine is genuine.
14. [**Indian pharma segment may not be impacted by Brexit**](#) – **Pharmabiz.com**
The Indian pharmaceutical segment is unlikely to be impacted adversely due to Britain's decision to move out of the European Union (EU) as the entire EU market accounts for around 12 per cent of India's total exports of pharmaceuticals. According to a CRISIL report, the share of the UK is only 3.5 per cent. However, few companies like Aurobindo and Wockhardt, with higher exposure to Europe, will see some impact. The Indian market closed lower significantly on Friday June 24 after the UK voted to leave the European Union. While the Sensex ended down 604 points at 26397, Nifty closed 181 points down at 8089. Selling was seen across sectors; major losers were capital goods, metal, realty and financial stocks. Relatively pharma shares were stable with small losses.